Clinical Updates

Five things for pharma marketers to know: Tuesday, December 8, 2015

Five things for pharma marketers to know: Tuesday, December 8, 2015

Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

Five things for pharma marketers to know: Tuesday, November 3, 2015

Five things for pharma marketers to know: Tuesday, November 3, 2015

GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development

Five things for pharma marketers to know: Tuesday, October 20, 2015

Five things for pharma marketers to know: Tuesday, October 20, 2015

Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

Five things for pharma marketers to know: Wednesday, August 19

Five things for pharma marketers to know: Wednesday, August 19

Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations

Five things for pharma marketers to know: Tuesday, August 18

Five things for pharma marketers to know: Tuesday, August 18

Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children

Five things for pharma marketers to know: Tuesday, August 11

Five things for pharma marketers to know: Tuesday, August 11

"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

Practice Fusion partners with AstraZeneca

Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.